Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
camrelizumab for Injection
DRUG
2 trials
Sponsors
Fudan University
, CNBG-Virogin Biotech (Shanghai) Ltd.
Conditions
Malignant Melanoma
Primary Hepatocellular Carcinoma
Phase 1
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
Not yet recruiting
NCT06124001
CNBG-Virogin Biotech (Shanghai) Ltd.
Primary Hepatocellular Carcinoma
Start: 2023-11-30
End: 2026-06-30
Target: 36
Updated: 2023-11-15
Phase 2
Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
NCT04593485
Fudan University
Malignant Melanoma
Start: 2020-10-28
End: 2023-12-31
Target: 40
Updated: 2020-12-23
Related Papers
Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study.
Journal of Clinical Oncology
2025-05-28
Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases
Oncology Letters
2024-04-03
2 citations